Cytek Biosciences Marks One Year Of Its 8,500-Sq-Ft Singapore Facility As APAC Expansion Reaches Major Milestone

One year after opening its 8,500-square-foot facility in Singapore, Cytek Biosciences, Inc. is celebrating a key milestone in its Asia-Pacific (APAC) expansion. The Singapore site has quickly grown into an important regional hub, supporting customers across APAC as well as other parts of the world. Over the past twelve months, the facility has played a major role in strengthening the company’s manufacturing capacity, improving after-sales service and training, and adding resilience to the global supply chain at a time when geopolitical and trade-related risks continue to impact technology and life sciences companies.

With life sciences research expanding rapidly across multiple countries, Cytek’s Singapore operations have become a vital part of its global manufacturing and support strategy. The facility helps accelerate scientific work, improves access to advanced cell analysis technologies, and supports the company’s long-term business growth in one of the fastest-growing regions for biomedical innovation.

“Establishing operations in Singapore has been a transformative step for Cytek,” said Wenbin Jiang, CEO of Cytek Biosciences. “In just one year, the facility has strengthened our manufacturing footprint, improved supply chain agility, and deepened our engagement with customers across APAC. This milestone reflects our commitment to investing in infrastructure that empowers scientists to move discovery forward.”

The decision to expand in Singapore was driven by the rising global demand for cellular analysis solutions. These technologies are increasingly used in immunology, immuno-oncology, infectious disease research, cancer diagnostics, and the development of new cancer therapies. As customer needs grew, Cytek aimed to scale production, shorten delivery timelines, and provide stronger technical support in the region. Over the past year, the Singapore site has achieved these goals by expanding manufacturing output and improving delivery efficiency for several APAC markets.

Beyond manufacturing, the facility also houses a dedicated service and training center. This center gives researchers and laboratory teams hands-on access to Cytek instruments and provides high-level technical training and support. This local availability has made it easier for customers to learn, troubleshoot, and optimize the use of Cytek’s advanced systems without relying on long-distance support.

“Cytek Biosciences’ new facility has been a welcome addition to Singapore’s MedTech ecosystem,” said Marcus Dass, Senior Vice President and Head of Global Enterprises at the Singapore Economic Development Board. “The investment strengthens our advanced manufacturing capabilities and contributes to life sciences research through the company’s cell analysis technologies. We are also heartened to see Cytek Biosciences working with our Institutes of Higher Learning and Research Institutes to drive innovation and talent development.”

With its first year now complete, the Singapore facility stands as a strong foundation for Cytek’s continued expansion in the APAC region. It supports scientists, strengthens global operations, and reinforces the company’s commitment to advancing high-quality cell analysis technologies worldwide.